Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Congratulations to Professor Andrew Pollard who is the Winner of the Policy Engagement category in the Vice-Chancellor Innovation Awards 2020 for his work on Global policy on typhoid vaccines through research at Oxford!

Nepal typhoid study participants. Image credit: Gates Archive/Samantha Reinders

Global policy on typhoid vaccines through research at Oxford

Typhoid affects 14 million people each year, with the highest rates in children, and causes around 150,000 deaths.

The disease, which is increasingly resistant to antibiotics, is spread through contaminated food and water in countries with lack of infrastructure but vaccines offer a potential rapid impact on this disease while definitive investment in infrastructure is awaited.

In order to accelerate vaccine introduction, the team led by Professor Andrew Pollard developed a model of human infection in Oxford in which volunteers drank a suspension of typhoid bacteria to deliberately get typhoid infection, so that they could test new vaccines. They studied the model carefully and made some important new observations about how the bacteria cause disease identified potential new approaches to diagnosis.

Professor Andrew PollardProfessor Andrew Pollard
 

They tested a new generation typhoid vaccine using the Oxford model and showed that it worked. The data from this study supported World Health Organisation (WHO) global policy recommendations on use of the vaccine for all children from 9 months to 15 years of age in high burden areas, and release of $85M funding by the Global Alliance for Vaccines and Immunisation (Gavi) to help low income countries introduce the vaccine.

Data on disease burden is important for countries to decide whether to prioritise vaccine introduction. The team led studies in Nepal, Bangladesh and Malawi to provide burden data in field studies of 100,000 people in each country. These data were also considered by WHO in their deliberations on global policy and provided a base for large field trials which they have undertaken to evaluate implementation of typhoid vaccine funded by the Bill & Melinda Gates Foundation. In these trials they have vaccinated over 100,000 children against typhoid and found that the vaccine prevented 82% of infections. They also showed that the vaccine was safe, data used by WHO in their policy position paper on typhoid vaccine safety.

Vaccine roll out has begun and 10 million doses were deployed at the end of 2019 to control an outbreak of typhoid resistant to most antibiotics in Pakistan. Many countries are now planning introduction of the vaccine as global roll out begins, with the next deployments being in Zimbabwe and Liberia.

Funded by the Bill and Melinda Gates Foundation

About the awards

The Vice-Chancellor Innovation Awards celebrate research-led innovation that is having societal or economic impact. Building on the awards two years ago a new category of Policy Engagement has been added to those for TeamworkBuilding CapacityInspiring Leadership, and Early Career Innovator.

Winners and Highly Commended entries were selected by the Vice-Chancellor’s Innovation Awards panel chaired by Professor Chas Bountra, Pro-Vice-Chancellor for Innovation, and comprising academics from each of the four Divisions and Professional Services staff who support impact and innovation across the collegiate University

You can find out more about the Awards and all of 2020’s Winners and Highly Commended entries on the Vice-Chancellor’s Innovation Awards pages.

 

 

Similar stories

Professor Sir Andrew Pollard Awarded the James Spence Medal in 2022

Professor Sir Andrew Pollard, BSc MA MBBS MRCP(UK) FRCPCH PhD DIC FHEA FIDSA FMedSci, is Professor of Paediatric Infection and Immunity at the University of Oxford, Honorary Consultant Paediatrician at Oxford Children’s Hospital and Vice Master of St Cross College, Oxford.

Professor Sue Ann Costa Clemens awarded an Honorary CBE

Congratulations to Professor Sue Ann Costa Clemens for her Honarary CBE award for her positive contribution towards public health. Here at the Oxford Vaccine Group and the Paediatrics department, we are extremely proud of what Sue and her team have achieved.

University of Oxford researchers among recipients of Ireland and UK joint research awards for digital humanities in €6.5m boost for interdisciplinary research partnerships

Dr Samantha Vanderslott (Oxford Vaccine Group) and Dr Claas Kirchhelle (University College Dublin) have had their three-year project ‘Typhoid, Cockles, and Terrorism’ about the history of typhoid in Dublin successfully funded.

Oxford Vaccine Group among winners at NHS Parliamentary awards

Researchers behind the Oxford AstraZeneca coronavirus vaccine have been recognised for their excellence at a healthcare awards ceremony.

OVG's director recognised in Queen’s Birthday Honours

Andrew Pollard, Director of the Oxford Vaccine Group, and Professor of Paediatric Infection and Immunity, becomes a Knight Bachelor for services to Public Health, particularly during the COVID-19 Pandemic.

Professor Matthew Snape named NIHR Senior Investigator

Four academics supported by the NIHR Oxford Biomedical Research Centre have been awarded a prestigious national award, among them Matthew Snape from the Oxford Vaccine Group.